KUALA LUMPUR, Oct 16 — Private specialist doctors say health insurers in Malaysia are increasingly denying coverage for essential medicines, from common chronic-disease drugs to life-saving biologics.
These insurance denials – spanning across innovators and generics, expensive and cheap medications – force patients to downgrade treatment, delay care, or abandon it altogether, reported specialists practising in private hospitals across the country.
Responses from CodeBlue’s recent nationwide survey of 855 private specialists reveal a pervasive pattern of interference, with insurers overriding prescriptions, insisting on cheaper substitutes, or classifying necessary drugs as “non-medical” or “not indicated”.
In insurance policy language, “non-medical” generally refers to expenses deemed not essential to treatment, such as supplements or cosmetic procedures, while “not medically indicated” means a treatment is considered unnecessary for a condition.
Doctors across multiple disciplines say these terms are now being misused by health insurance/takaful companies and third-party administrators (TPAs) to deny legitimate therapy.
Generic-Only Mandates Over Clinical Judgement
Several specialists complained about generic-only mandates from insurance companies or TPAs. Some also raised concerns about hospital-insurer arrangements that appeared to influence prescriptions without their direct input.
A cardiologist in Johor said he was aware of “backdoor agreements” that pressured hospitals to use generics instead of branded drugs.
“Patients who have paid for premium insurance have at times complained and asked me why they have been auto-switched without consultation,” he said.
Specialists said insurers’ preference for generic substitution can interfere with treatment decisions, particularly when patients respond differently to branded and generic formulations.
An ophthalmologist in Johor recounted a case where an insurer insisted on using a generic version of Augmentin, which triggered an allergic reaction in a patient who had tolerated the original antibiotic brand without issue.
An anaesthesiologist in the Klang Valley said he sees real-world differences in antibiotic performance. “Some generics are fine,” he noted, “but antibiotics is one area where I can clearly see a difference between generics and originals. But profits prevail over efficacy.”
IV painkiller Dynastat was also cited as another denial, with insurers insisting on the generic versions. Insurers deny coverage of Ozempic for severe obesity and diabetes too.
Chronic Illness Drugs Denied For Cost, Not Science
The survey also revealed that insurers often deny or challenge prescriptions for treatments, including first-line therapies, by citing outdated criteria or narrow interpretations of what counts as a covered condition.
A nephrologist in the Klang Valley said kidney disease patients frequently face such hurdles, especially when insurers restrict coverage for related conditions.
“Kidney disease patients often have multiple comorbidities that include hypertension, diabetes, high cholesterol, renal anaemia and bone disease. Frequently, insurers forbid prescriptions if the medications are for the aforementioned comorbidities, citing the reason as ‘Not Related to the Diagnosis’,” the specialist wrote.
The same respondent added that even prescribing SGLT2 inhibitors for kidney patients is often challenged “because patients have no diabetes” – suggesting a narrow knowledge that most medications have multiple indications of use.
An interventional radiologist in Sabah observed that the assessors are “not doctors” and their knowledge is “not updated”, hence why insurers refer to older treatment options.
A nuclear medicine specialist in Penang made a similar point, saying those who vet claims have no knowledge of what they are asking. “They are not updated with the latest clinical practices and just rely on MOH’s (Ministry of Health) 13th Schedule and MMA’s (Malaysian Medical Association) 5th Schedule.” These schedules contain the fees and codes for procedures.
An ophthalmologist in the Klang Valley said such practices show how insurers’ decisions are increasingly shaping medical access: “Health care insurance has so much power that they are influencing access to health care and health care priorities, and hampering advancements in medical innovation and progress.”
Several specialists noted that insurance denials were not limited to high-cost or innovative drugs. Even standard and widely used treatments were often rejected when insurers deemed the therapy unnecessary or misclassified the indication.
An internal medicine specialist in the Klang Valley cited the case of semaglutide, a GLP-1 receptor agonist used to treat diabetes. “Semaglutide for diabetes. They claim the indication is for weight loss,” the clinician said.
An endocrinologist from the same region said similar rejections occur for patients with both diabetes and obesity. “Patients with diabetes and obesity fare better with GLP-1, but insurance won’t cover it because they say it’s a weight loss medication, when it’s actually used for diabetes,” the specialist explained.
Doctors said such denials show how insurers’ narrow reading of drug indications can override medical judgment and undermine long-term disease management.
Specialists also reported that even inexpensive or routine medications were rejected when insurers classified them as unnecessary therapy or “supplements.”
A paediatrician in Sarawak recounted: “Patients with anaemia had iron studies done and started on iron replacement therapy, but were told by the insurer that iron studies were not warranted and iron replacement therapy was considered a supplement.”
Another paediatrician in the Klang Valley described a similar case involving a child admitted for rotaviral gastroenteritis with dehydration. “Child admitted for rotaviral AGE with dehydration. Noted haemoglobin (Hb) was 7 (anaemia). Did further investigation and started on iron and multivitamin supplements. Insurance refused to pay for the tests and treatment because it is a supplement. Patient had to pay and was referred to a government hospital.”
Specialists said such exclusions, from advanced biologics to basic supplements, reflect a broader pattern of insurers narrowing the definition of what counts as “medical care”. Treatments are often denied not because they lack clinical value, but because they fall outside rigid or outdated policy interpretations.
Meanwhile, specialists in oncology, rheumatology, gastroenterology, and respiratory medicine said insurers frequently excluded newer or biologic drugs by labelling them “experimental” or “not medically indicated”, even when the medicines are approved by the MOH and recommended in international clinical guidelines.
Doctors cited repeated denials for biologics and targeted therapies such as Humira, Stelara, vedolizumab, rituximab, Phesgo, and Xolair, used to treat conditions like rheumatoid arthritis, lupus, Crohn’s disease, leukaemia, breast cancer, and severe asthma.
One oncologist in the Klang Valley said insurers refused coverage for life-saving radiotherapy because the treatment was classified as an outpatient procedure.
“I have had patients whose cancer progressed or became incurable because their insurance denied GL (guarantee letter) for radiotherapy and patients were unable to afford treatment,” she said.
A rheumatologist in KL/Selangor said a patient with severe inflammatory spondylitis that left them wheelchair-bound was denied daycare admission coverage for IV biologic infusions for effective treatment control, as per worldwide standard protocols, because insurers claimed that the treatment could be done as outpatient.
“This is impossible as IV infusion treatment cannot be conducted in an outpatient clinic setting,” he said, adding that an insurance company specifically denied coverage of all forms of IV infusion treatment in daycare wards as their policy only allowed daycare surgery.
Others said insurers refused to cover supportive or palliative care medications, such as pain relief and symptom management at the end of life, forcing terminally ill patients to pay cash.
Everyday Medicines And Women’s Health Dismissed As ‘Non-Medical’
Specialists also highlighted insurers’ refusal to cover common treatments that form part of standard medical care.
Women’s health medications were frequently denied. Several gynaecologists said insurers rejected claims for the Mirena intrauterine system – not as contraception, but as treatment for heavy menstrual bleeding – calling it a “contraceptive device” and therefore excluded.
An obstetrics and gynaecology (O&G) specialist in Sarawak said: “Mirena. It is used for treatment of heavy menstrual bleeding but TPAs will insist it’s a contraception device and refuse to pay.”
Another O&G specialist in the Klang Valley similarly cited insurance denials of Mirena, adding: “Oral haematinics for treatment of an anaemic patient are not covered as they are regarded as ‘supplements/vitamins.’”
Doctors warned that when insurers refuse to cover the right medicine, patients are often forced to delay or forgo treatment, leading to worsening disease, avoidable complications, or permanent disability.
Several respondents said patients who could not afford to pay out of pocket defaulted treatment entirely or were transferred to public hospitals, disrupting continuity of care.
Others said patients who switched to cheaper generics developed complications or poorer disease control, particularly in chronic conditions that require stable, long-term management.
CodeBlue’s survey findings suggest that denial of drug claims is not an isolated problem, but part of a wider pattern where insurers use fine print, cost controls, and opaque policies to limit payouts, often at the expense of clinical outcomes.
Whether through outright refusals, forced substitution, or redefining what counts as “medical,” specialists said the result is the same: patients get less care than what they paid for.
This is the third article in CodeBlue’s series on health insurance practices in Malaysia, based on CodeBlue’s nationwide survey among private specialists. The next story will examine insurers’ use of irrelevant or excessive questions that delay or obstruct patient care.
Read the first article headlined Poll: Nearly All Specialists Perceive Insurer Interference With Clinical Decisions and the second article titled ‘Deny, Delay, Revoke’: Specialists Reveal Health Insurance Underbelly In Malaysia.
